Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ILK | Q13418 | 3/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.36 |
| ▸ | GFER | P55789 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL7043082 | 0.91 | KMT2A (0.38) | GAASMN1; SMN2MAPTALDH1A1HPGD | |
| SCHEMBL2402669 | 0.84 | DRD1 (0.47) | GAAMAPTALDH1A1ILKGFER | |
| SCHEMBL7038644 | 0.83 | GAA (0.37) | GAASMN1; SMN2MAPTALDH1A1HPGD | |
| SCHEMBL5785398 | 0.82 | GAA (0.38) | GAASMN1; SMN2MAPTALDH1A1HSD17B10 | |
| SCHEMBL5729227 | 0.80 | IKBKB (0.36) | GAAMAPTILKDYRK1ARAB9A | |
| SCHEMBL5730488 | 0.76 | ALDH1A1 (0.57) | GAAMAPTALDH1A1HPGDHSD17B10 | |
| SCHEMBL13516427 | 0.76 | MAPT (0.50) | GAASMN1; SMN2MAPTALDH1A1HPGD | |
| SCHEMBL20722970 | 0.76 | AKT2 (0.42) | GAAMAPTALDH1A1HSD17B10ILK | |
| SCHEMBL1868350 | 0.75 | HSP90AA1 (0.48) | GAAMAPTALDH1A1HPGDHSD17B10 | |
| SCHEMBL12326164 | 0.74 | ALDH1A1 (0.59) | GAAALDH1A1HPGDACHEKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1218381-B1 | AMINO SUBSTITUTED PYRAZOLO¬1,5-a|-1,5-PYRIMIDINES AND PYRAZOLO¬1,5-a|-1,3,5-TRIAZINES | NEUROGEN CORP (US) | 2006-12-06 | — | — | EP | disclosed |
| US-20030069246-A1 | Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo [1,5-a]-1,3,5-triazines | NEUROGEN CORPORATION (US) | 2003-04-10 | — | — | US | disclosed |
| US-6476038-B1 | Amino substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines | NEUROGEN CORPORATION | 2002-11-05 | — | — | US | disclosed |
| EP-1218379-A2 | CERTAIN ALKYLENE DIAMINE-SUBSTITUTED PYRAZOLO 1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO 1,5-a]-1,3,5-TRIAZINES | NEUROGEN CORPORATION (US) | 2002-07-03 | — | — | EP | disclosed |
| EP-1218381-A2 | AMINO SUBSTITUTED PYRAZOLO 1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO 1,5-a]-1,3,5-TRIAZINES | NEUROGEN CORPORATION (US) | 2002-07-03 | — | — | EP | disclosed |
| US-6372743-B1 | EATING DISORDERS, HYPOTENSIVE AGENTS AND CARDIOVASCULAR DISORDERS | NEUROGEN CORPORATION | 2002-04-16 | — | — | US | disclosed |
| WO-2001023387-A2 | CERTAIN ALKYLENE DIAMINE-SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES | NEUROGEN CORPORATION (US) | 2001-04-05 | — | — | WO | disclosed |
| WO-2001023388-A2 | AMINO SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES | NEUROGEN CORPORATION (US) | 2001-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069246-A1 | Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo [1,5-a]-1,3,5-triazines | NPY1R, NPY5R, NPY2R | GAA 3225/4885SMN1; SMN2 1881/4885MAPT 2820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.